

1 **Isoniazid preventive therapy completion and factors**
2 **associated with non-completion among patients on**
3 **antiretroviral therapy at Kisenyi Health Centre IV,**
4 **Kampala, Uganda.**

5 **Short title: Isoniazid preventive therapy completion among**
6 **patients on antiretroviral therapy in Kampala - Uganda.**

7 **Ian Amany^{1,5*}, Michael Muhoozi¹, Dickson Aruhomukama^{2,3,5}, Anthony**
8 **Ssebagereka¹, Richard Mugambe⁴.**

9 ¹Department of Epidemiology and Biostatistics, School of Public Health, College of
10 Health Sciences, Makerere University.

11 ²Department of Medical Microbiology, School of Biomedical Sciences, College of
12 Health Sciences, Makerere University.

13 ³Department of Immunology and Molecular Biology, School of Biomedical Sciences,
14 College of Health Sciences, Makerere University.

15 ⁴Department of Disease Control and Environmental Health, School of Public Health,
16 College of Health Sciences, Makerere University.

17 ⁵Brainmann Analytics, Kampala, Uganda

18 *Corresponding author

19 Email: ianamanya24@gmail.com (IA)

20 Abstract

21 **Background:** Isoniazid preventive therapy (IPT) is given to HIV patients to reduce the
22 risk of active tuberculosis (TB). However, treatment completion remains sub-optimal
23 among those that are initiated. This study aimed to determine the completion level of
24 IPT and the factors associated with non-completion among people on antiretroviral
25 therapy (ART) at Kisenyi Health Center IV in Kampala, Uganda.

26 **Methods:** A facility-based retrospective cohort study utilizing routinely collected data
27 of 341 randomly selected HIV patients initiated on IPT was conducted. Data extracted
28 from the registers were used to determine the IPT completion. Modified Poisson
29 regression with robust error variances was used to determine the associated factors
30 of IPT non-completion while in-depth interviews were conducted to explore barriers to
31 IPT completion from the patient's perspective.

32 **Results:** A total of 341 patients who started on isoniazid (INH) were retrospectively
33 followed up, with 69% (236/341) being female. Overall IPT completion was at 83%.
34 Multivariable analysis revealed the prevalence of IPT non-completion among males
35 was 2.24 times the prevalence among females [aPR 2.24, 95% CI: 1.40-3.58]. The
36 prevalence of IPT non-completion among patients with a non-suppressed HIV viral
37 load was 3.00 times the prevalence among those with a suppressed HIV viral load
38 [aPR 3.00, 95% CI: 1.44-6.65]. Patients who were married/cohabiting had a 69% lower
39 prevalence of IPT non-completion compared to those who were single [aPR 0.31, 95%
40 CI: 0.17-0.55]. Lack of IPT-related health education, pill burden, distance to the health
41 facility, and patient relocation were reported as the barriers to IPT completion.

42 **Conclusion:** IPT completion was found to be at 83% among the cohort studied.
43 However, lower completion levels persist among males and HIV virally non-

- 44 suppressed patients. Lack of IPT-related health education, pill burden, distance to the
- 45 health facility, and patient relocation were reported as the barriers to IPT completion.
- 46 Interventions that target these groups of people need to be intensified.

47 **Background**

48 The World Health Organization (WHO) estimates a quarter of the world's population
49 to be infected with latent Tuberculosis of which the majority live in sub-Saharan Africa
50 which is home to about 14% of the global population (1). An estimated 10 million
51 people developed TB disease in 2017 of whom 72% were living in sub-Saharan Africa,
52 of those that developed TB disease, 9% were co-infected with HIV (1). Immune
53 suppression particularly due to HIV infection greatly increases the risk of TB infection
54 as well as latent TB progression to an active infection (2, 3). The risk of developing TB
55 is 20 to 37 times greater in people living with HIV (PLHIV) than among those who do
56 not have HIV (4). Antiretroviral therapy (ART) has been reported to reduce the risk of
57 acquiring TB (5) though the risk remains higher in people with HIV; and these people
58 are up to four times more likely to die during TB treatment (6, 7).

59 Uganda had an estimated 1.4 million people living with HIV in 2018, of whom 72%
60 were on ART (8). Uganda also registered about 86,000 new TB infections in 2017 of
61 whom an estimated 40% were co-infected with HIV. Among these HIV patients, TB
62 accounted for about 30% of all deaths (1). In Kampala, the prevalence of HIV is
63 estimated to be about 6.9%, which is higher than the national average of 6.2% (9).
64 Additionally, the Uganda national TB prevalence survey of 2014/15 revealed a higher
65 bacteriologically confirmed (B+) TB prevalence of 504/100,000 in urban areas
66 compared to 370/100,000 in rural areas (10). Kampala had the highest TB case
67 notifications in Uganda suggesting that TB was more common in urban areas than in
68 rural areas.

69 WHO recommends the use of three I's (Isoniazid Preventive Therapy (IPT), intensified
70 case finding, and infection control) to reduce the risk, and burden of TB in people living

71 with HIV (11). IPT use reduces the risk of TB disease among HIV-infected individuals
72 by about 60% (12, 13), and this efficacy is even higher accompanied by ART (14). IPT
73 also prevents the progression of latent TB to active TB disease (15).

74 In 2014, Uganda adopted WHO's guidelines that recommended the use of IPT for TB
75 prevention as part of the comprehensive HIV/AIDS care strategy (16). Despite the
76 available evidence that IPT is effective, many countries including Uganda have had
77 little success in implementing this recommendation (1). In Uganda, the uptake of IPT
78 as part of the TB prevention strategy remains low and this has mainly been attributed
79 to limited funding for IPT commodities, lack of awareness of the potential benefits of
80 IPT, health facilities, district & implementing partners not being held accountable for
81 IPT performance; lack of data utilization at national, district & health facility level and
82 lack of sustained quality mentorship among other factors (17).

83 In addition, adherence and completion of treatment among patients initiated on IPT
84 remain major concerns as these affect its effectiveness (14). Limited studies
85 conducted in Ethiopia, Uganda, and Malawi respectively, have documented
86 completion levels of IPT ranging from 36 to 98% (18-20).

87 However, few studies had documented patient reasons for failure to complete the
88 treatment in Uganda. Understanding this was key to improving the use of IPT among
89 ART patients. Using routinely collected data, this study aimed to assess the
90 completion of IPT and factors associated with non-completion among patients on ART.
91 This would inform stakeholders, help to improve IPT use and help realize its benefits
92 thereby reducing the risk and burden of TB among these people.

93 **Materials and methods**

94 **Study area**

95 Kampala, Uganda's capital has an estimated resident population of 1.5 million people
96 (21). However, the total population attracted by the various economic activities and
97 services in almost doubles the resident population. The study was conducted at
98 Kisenyi health centre IV in Kampala's central division. Kisenyi health centre IV was
99 purposively selected as it's the largest operational health center IV in Kampala that
100 also receives a high volume of patients in comparison to smaller health facilities that
101 provide HIV care. The facility is financed by the government but also receives funding
102 from donors through implementing partners. Services offered by this facility are free
103 and include TB services, laboratory services, dental services, HIV counseling and
104 testing, maternity services, Antenatal/EMTCT services, immunization, Early Infant
105 Diagnosis (EID), Nutrition services, Family planning services, Postnatal services,
106 Cancer screening, STI management, youth-friendly services, and comprehensive ART
107 outreaches among others. The ART and TB clinics are integrated and open from
108 Monday through Friday to accommodate the nearly 12000 active ART patients. To
109 increase completion rates, IPT and ARV medicine refills are given out simultaneously
110 with synchronized durations. A number of tools, including the ART dispensing logs,
111 IPT registers, ART cards, the ART register, the viral load log, and the daily activity
112 consumption log, among others, record the drugs that have been prescribed. The
113 patient appointment and visit dates, patient ID, current ART regimen, number of drug
114 days distributed, weight and height, and whether the patient was bled for viral load or
115 CD4 are just a few of the details recorded in these instruments. Active registers are
116 kept at the various service stations, and the tools are housed in a separate records

117 room. The Uganda Electronic Records Management system (UgandaEMR), which is
118 located in the records sector, also stores this data electronically.

119 **Study design**

120 This was a facility-based retrospective cohort study utilizing routinely collected data.
121 Quantitative data extracted from the facility registers were used to answer the
122 questions on completion of IPT and the factors associated with non-completion while
123 qualitative data collected through in-depth interviews with patients were used to
124 explore the barriers to IPT completion from a patient's perspective.

125 **Study population**

126 The study participants were HIV patients on ART at Kisenyi HC IV that had been
127 initiated on IPT. To reduce recall bias, ART patients that had been initiated on IPT in
128 September 2019 at Kisenyi HC IV were considered.

129 **Inclusion criteria**

130 Only ART patients initiated on IPT in September 2019. Purposively selected non-
131 completing ART patients for in-depth interviews who provided informed consent.
132 Minors who provided assent and whose caretakers provided consent were included in
133 the study.

134 **Exclusion criteria**

135 ART patients initiated on IPT in any period other than September 2019 and those
136 whose records could not be traced or found at the facility were excluded from the
137 study. Patients who were ill, unavailable at the time of data collection and those who
138 had no phone contacts were excluded from in-depth interviews.

139 **Sample size considerations**

140 To determine the completion of IPT and the factors associated with non-completion,
141 the Yamane formula at a 0.05 level of precision was used (22). This formula was used
142 due to the finite population of patients initiated on IPT.

$$143 \quad n = N / [1 + N (E)^2]$$

144 Where; n = sample size, N = population size, E = level of precision.

$$145 \quad n = 1166 / [1 + 1166 (0.05)^2]$$

$$146 \quad n = 298$$

147 Adjusting for a 10% loss to follow-up

148 The minimum sample size required was 331.

149 **Sampling procedure**

150 A list of the patient IDs initiated on IPT during September 2019, was compiled. A
151 random sample of 341 patients was drawn, and their records were extracted from the
152 IPT registration using Microsoft Excel. Respondents for in-depth interviews were
153 purposively selected from the list of non-completers. The respondent selection was
154 stratified by age group, sex, marital status, and district of residence (Table 1).

155 **Table 2: Planned and conducted In-depth interviews.**

	Planned Interviews	Conducted Interviews
Characteristic	Number	Number
Sex		
Male	9	7
Female	9	8
Age group		
0-9	3	0
10-19	3	1

20-29	3	5
30-39	3	4
40-49	3	3
50+	3	2
Marital status		
Single	5	4
Married/cohabiting	5	6
Separated/divorced	5	5
Widowed	3	0
District of Residence		
Kampala	6	8
Wakiso	6	6
Others	6	1

156 In a phone call, the participants gave their permission to participate in the form of audio
157 that was recorded. Interviews continued until they reached saturation.

158 **Study variables**

159 **Dependent variable**

160 The IPT non-completion, which was measured as a person failing to pick up their fifth
161 consecutive monthly refill within 6 months of initiation, was the dependent variable.

162 Patients who had begun IPT had to return to the medical facility every month for five
163 months starting after a 2-week assessment for any adverse effects. IPT refills were
164 given by clinicians at the monthly visit, and they also evaluated the patient's adherence
165 and side effects. INH was prescribed for multiple months to patients who received ART
166 on a multi-month dispensation.

167 It is important to note that the Ministry of health recommends that IPT should be given
168 to all patients with the following criteria: HIV-positive children (\geq one year of age),
169 adolescents, and adults with no signs and symptoms of TB; HIV-positive infants and
170 children $<$ 5years who have no signs and symptoms and active TB disease who get in
171 contact with a person with active TB disease, irrespective of previous TPT; HIV-

172 positive pregnant mothers with a history of contact with a TB patient after ruling out
173 active TB; HIV-positive pregnant mothers with a WHO Stage 3 or 4 event and/or CD4
174 <200 without active TB (23).

175 **Independent variables**

176 The independent variables included; age, sex, Body Mass Index (BMI), marital status,
177 WHO HIV clinical stage at IPT initiation, and pre-IPT HIV viral suppression (defined as
178 the most recent measurement within 12 months to IPT initiation).

179 **Data collection tools**

180 The qualitative data was collected using a call recorder and an in-depth interview
181 guide, and the quantitative data was extracted using a data extraction tool.

182 **Data collection procedures**

183 Data collection ran for one month. Quantitative data were extracted from the IPT
184 register, ART cards, and the Uganda Electronic Medical Records system (EMR) using
185 a structured data tool. Variables captured quantitatively were; Residence (District, sub-
186 county, village), WHO HIV stage at the time of IPT initiation, IPT refill and next
187 appointment dates, weight, height, age, sex, pre-IPT viral load result, and marital
188 status. In-depth interviews that lasted 20-30 minutes were conducted by a trained
189 research assistant with the help of an interview guide. Variables explored qualitatively
190 included; IPT-related health education, challenges encountered while on IPT, and
191 smoking and/or alcohol consumption. These variables gave rise to some of the themes
192 presented in the findings. The interviewer introduced herself to the respondent,
193 informed him/her about the aim of the study, duration of the interview, potential risks
194 or benefits of participating in the study, and then sought consent to take part in the

195 study. All qualitative interviews were recorded with a call recording application and
196 notes taken during the interviews.

197 **Quality control**

198 **Training of research assistants**

199 Two graduate research assistants were recruited and trained to take part in the study
200 to standardize data collection procedures. The training involved a review of the study
201 objectives, variables to be extracted, data sources and collection procedures, ethics,
202 and confidentiality. The training ensured that the research assistants were confident,
203 knowledgeable, and comfortable with the extraction tools, data sources, and
204 procedures.

205 **Pre-testing of the tools**

206 Both the data extraction tool and interview guide were pre-tested at Kawaala Health
207 Centre III which is a public health facility in Rubaga division, Kampala district. The
208 tools were then appropriately adjusted based on the results from the pre-test to ensure
209 that all the available and relevant data was captured.

210 **Field editing of data**

211 The principal investigator supervised the data collection exercise regularly and met
212 with the research assistants to address any issues that arose, share experiences,
213 lessons learned, and guide the way forward. Accuracy and completeness of all filled
214 data collection tools were emphasized and checked daily before submission.

215 **Data management and analysis**

216 **Data storage and entry**

217 Raw data in form of complete tools were safely kept in a lockable shelf. The data was
218 then entered into a password-protected data entry screen in MS Excel that was
219 developed by the PI before being exported to STATA version 14.0 for cleaning and
220 analysis. Recordings of in-depth interviews with unique identifiers were secured with
221 a password, simultaneously transcribed, and translated to English verbatim. Each
222 transcript was proofread by the PI for content accuracy and completeness before
223 being exported to Atlas ti. version 6.0 for analysis. Final transcripts and dataset were
224 securely stored on a password-protected computer and backed up on a secure cloud-
225 based account.

226 **Data analysis**

227 **Quantitative data**

228 **Data entry, cleaning, and sorting;** data was entered into a developed excel data
229 screen, and checked for completeness and logical flow. The goal was to understand
230 and identify variables to be used in the analysis. Output was a working dataset.

231 **Exploratory data analysis;** the nature of the variables was examined, new categories
232 and variables were generated, and unwanted variables were dropped at this stage.
233 The goal was to gain a deeper understanding of the data and variables. Output was
234 an analytic dataset.

235 **Descriptive analysis;** Characteristics of study participants were described using
236 frequencies categorical variables, mean, and SD for continuous variables. IPT non-

237 completion was determined as a proportion that failed to pick up their 5th consecutive
238 monthly refill within 6 months among those initiated.

239 **Bivariable analysis;** simple modified Poisson regressions of the outcome and the
240 predictor were run to determine factors associated with non-completion to be included
241 in the multivariable model. The output was crude prevalence ratios and confidence
242 intervals. Variables with a p-value <0.2 were selected for inclusion in the multivariable
243 model.

244 **Multivariable analysis;** a modified Poisson regression model with robust error
245 variances was run to determine the predictors of IPT non-completion. The output was
246 adjusted prevalence ratios with corresponding confidence intervals. Variables were
247 checked for multicollinearity before being added to the model. Variables with a p-value
248 <0.05 were significantly associated with IPT non-completion.

249 **Qualitative data analysis**

250 All audio recordings were concurrently transcribed and translated to English verbatim.
251 Transcripts were then proofread for accuracy by the PI before being uploaded to
252 Atlas.ti Version 6.0 for analysis. Data analysis was conducted by a trained data
253 analyst. Thematic analysis was used to analyze the data. Both inductive and deductive
254 coding approaches were applied to generate the codebook (24, 25). The codebook
255 generated during analysis was reviewed by the PI before adoption. After the review of
256 codes with the help of the code families' option in Atlas.ti, codes were then combined,
257 others dropped or renamed to fit under emerging themes. The results were presented
258 as narratives along with supporting quotes per theme. The analysis was regularly
259 reviewed by the PI at every stage to ensure the reflexivity of the interpretations.

260 **Ethical considerations**

261 Ethical approval for the study was sought and granted by Makerere University School
262 of Public Health Higher Degrees, Research and Ethics Committee. Permissions were
263 subsequently granted by the Director of Public Health Environment at KCCA and the
264 In-charge Kisenyi HC IV. Recorded consent was also obtained from the respondents.
265 The research assistants were trained on how to ensure privacy and confidentiality for
266 all participants both during and after data collection. Data collection took place at the
267 height of the COVID-19 Pandemic. As result, research assistants were provided with
268 adequate masks and sanitizer as part of infection prevention and control (IPC)
269 measures. In addition, In-depth interviews were conducted over the phone in place of
270 physical interviews for IPC reasons. Consequently, participant consent was audio
271 recorded.

272 **Results**

273 **Description of the study population**

274 A total of 341 records of participants were included in the analysis. About 31%
275 (104/341) of the participants were aged 29 years and below. The median age was 33
276 (IQR 28 - 40). The majority of the respondents were female comprising 69% (236/341)
277 and 54.5% (186) had a normal body weight. Additionally, 97.1% (331/341) of the
278 participants were at the WHO HIV clinical stage1. All the participants had a viral load
279 test done in the last 12 months with 97% (330) having a suppressed result. Regarding
280 marital status, 58.4% (199/341) of the participants were married/cohabiting while
281 20.5% (70) were Divorced/separated (Table 3).

282 **Table 4: Characteristics of the study population**

Characteristic	Frequency		
	Non-Completers (n) %	Completers (n) %	Overall (n)
Age	17% (58)	83% (283)	
0-29	20.2% (21)	79.8% (83)	104
30+	15.6% (37)	84.4% (200)	237
Sex			
Female	13.6% (32)	86.4% (204)	236
Male	24.8% (26)	75.2% (79)	105
BMI			
Normal weight	19.9% (37)	80.1% (149)	186
Underweight	22.2% (4)	77.8% (14)	18
Pre-obesity	14.1% (12)	85.9% (73)	85
Class 1 obesity	12.1% (4)	87.9% (29)	33
Class 2&3 obesity	5.3% (1)	94.7% (18)	19
WHO HIV clinical stage			
Stage 1	16.9% (56)	83.1% (275)	331
Stage 2&3	20.0% (2)	80.0% (8)	10
HIV Viral suppression			
Suppressed	15.8% (52)	84.2% (278)	330
Non-suppressed	54.6% (6)	45.4% (5)	11
Marital status			
Single	31.7% (19)	68.3% (41)	60
Married/cohabiting	9.5% (19)	90.5% (180)	199
Divorced/separated	24.3% (17)	75.7% (53)	70
widowed	25% (3)	75% (9)	12

283 Description of In-depth Interview participant characteristics

284 In total, 15 participants—eight women and seven men—who had not finished their IPT
285 took part in the qualitative study. Four of the individuals were single, six were married
286 or cohabitating, and five were divorced or legally separated. The median age was 34
287 overall (IQR: 28.5-45). One respondent lived in Mukono district, seven respondents
288 lived in Kampala district, six respondents lived in Wakiso district. Four participants had
289 completed their secondary education, four had completed their primary education, and
290 one had completed their tertiary or university education (Table 3).

291 Table 5: Characteristics of IDI respondents

Characteristic	Number
Sex	
Male	7
Female	8
Age	
Overall median age	34
Median age (male)	34
Median age (female)	35.5
Marital status	
Single	4
Married/cohabiting	6
Separated/divorced	5
Education level	
Primary education	14
Secondary education	4
Tertiary or university	1
District of Residence	
Kampala	8
Wakiso	6
Mukono	1

293 **IPT completion**

294 Of the 341 persons who started INH, 83% (283) patients finished the dose, compared
295 to 17% (58) who did not. 86.4% (204) of the female participants in the IPT finished it,
296 whereas 13.6% (32) did not. In terms of guys, 75.2% (79) finished IPT while 24.8%
297 (26) did not. 84.2% (278) of patients with a suppressed HIV viral load finished IPT,
298 while 15.8% (52) did not. 54.6% (6) of individuals with a non-suppressed HIV viral load
299 did not finish IPT, compared to 45.4% (5) who did. IPT was successfully completed by
300 79.8% (183) of patients who were under the age of 29, compared to 20.2% (21) who
301 were not. About 91% (180) of the patients who were married or cohabitated completed
302 IPT, compared to 9.5% (19) who did not.

303 **Factors associated with IPT non-completion**

304 **Bivariable analysis**

305 The prevalence of IPT non-completion was 23% lower among patients aged 30 years
306 and above compared to those aged 29 years and below [Crude PR 0.77, CI: 0.48-
307 1.25]. Males had an 83% higher prevalence of IPT non-completion compared to
308 females [Crude PR 1.83, 95% CI: 1.15-2.91]. Patients with a non-suppressed HIV viral
309 load had a 2.46 higher prevalence of IPT non-completion compared to those with a
310 suppressed HIV viral load [Crude PR 3.46, 95% CI: 1.91-6.28]. Patients who were
311 married/cohabiting had a 70% lower prevalence of IPT non-completion compared to
312 those who were single [Crude PR 0.30, 95% CI: 0.17-0.53].

313 **Multivariable analysis**

314 In multivariable analysis, factors significantly associated with IPT non-completion
315 were; sex, HIV viral suppression, and marital status. The prevalence of IPT non-
316 completion among males was 2.24 times the prevalence among females [aPR 2.24,

317 95% CI: 1.40-3.58]. The prevalence of IPT non-completion among patients with a non-
 318 suppressed HIV viral load was 3.00 times the prevalence among those with a
 319 suppressed HIV viral load [aPR 3.00, 95% CI: 1.435-6.65]. Patients who were
 320 married/cohabiting had a 69% lower prevalence of IPT non-completion compared to
 321 those who were single [aPR 0.31, 95% CI: 0.17-0.55] (Table 6).

322 **Table 7: Bivariable and multivariable analysis.**

Variable	Completed IPT		Crude	Adjusted
	No % (n)	Yes % (n)	Prevalence Ratios	Prevalence Ratios (aPR)
Overall	17% (58)	83% (283)	N/A	N/A
Age				
0-29	20.2% (21)	79.8% (83)	1.00	--
30+	15.6% (37)	84.4% (200)	0.77 (0.48-1.25)	--
Sex				
Female	13.6% (32)	86.4% (204)	1.00	1.00
Male	24.8% (26)	75.2% (79)	1.83 (1.15-2.91) *	2.24 (1.40-3.58) **
WHO HIV clinical stage				
Stage 1	16.9% (56)	83.1% (275)	1.00	--
Stage 2&3	20.0% (2)	80.0% (8)	1.18 (0.33-4.19)	--
HIV Viral load status				
Suppressed	15.8 (52)	84.2 (278)	1.00	1.00
Non-suppressed	54.6 (6)	45.4 (5)	3.46 (1.91-6.28) ***	3.00 (1.35-6.65) **
Marital status				
Single	31.7 (19)	68.3 (41)	1.00	1.00
Divorced/separated	24.3 (17)	75.7 (53)	0.77 (0.44-1.34)	0.77 (0.43-1.38)
Married/cohabiting	9.5 (19)	90.5 (180)	0.30 (0.17-0.53) ***	0.31(0.17-0.55) ***
Widowed	25 (3)	75 (9)	0.79 (0.28-2.26)	1.07 (0.35-3.24)
BMI				
Normal weight	19.9% (37)	80.1% (149)	1.00	--

Underweight	22.2% (4)	77.8% (14)	1.12 (0.45-2.78)	--
Pre-obesity	14.1% (12)	85.9% (73)	0.71 (0.40-1.30)	--
Class 1 obesity	12.1% (4)	87.9% (29)	0.61 (0.23-1.60)	--
Class 2&3 obesity	5.3% (1)	94.7% (18)	0.26 (0.38-1.83)	--

323 **Level of significance <0.05*; <0.01**; <0.001*****

324 **Barriers to IPT completion**

325 Themes and subthemes that emerged were;

326 Theme; Knowledge about IPT.

327 Theme: Challenges encountered while taking IPT. Subthemes: Lack of transport,

328 Distance to the health facility, Pill burden, Relocation.

329 **Theme; Knowledge about IPT**

330 One of the reasons for non-compliance was the absence of IPT-related health
331 education. The respondent was unaware of his IPT initiation.

332 *"...I met a friend at the garage where I work who disclosed that he was on drugs and*
333 *had not received IPT all his life. So, I wondered why I had been given these tablets*
334 *yet the doctor didn't tell me I had TB, I swallowed them for 2 months and got tired and*
335 *stopped"* single male patient

336 **Theme: Challenges encountered while taking IPT**

337 **Subtheme: High pill burden**

338 High pill burden was another reason for IPT non-completion. This was more
339 pronounced among patients that had to take other drugs for other pre-existing
340 conditions such as hypertension in addition to ART and IPT.

341 *“...the tablets to swallow are very many, I have these ART tablets, then my*
342 *hypertension tablets, and then the IPT. So, at times I’d forget to swallow the IPT as it*
343 *wasn’t treating me for anything and I completely stopped after forgetting it thrice”*

344 Female Patient.

345 **Subtheme: Distance to the health facility**

346 Distance to the health facility was cited as a challenge as some of the patients could
347 not afford transport every month to the health facility to pick up their IPT doses.

348 *“...the first challenge, most of us come from far and at the beginning they first gave*
349 *me for a month and most of my work I am casually employed. So sometimes it would*
350 *be hard for me to tell my boss there is somewhere I am going I will not be around now”*

351 Male Patient.

352 **Subtheme: Relocation**

353 Change of business and relocation from one place to another was cited as another
354 reason for IPT non-completion

355 *“...when I shifted from Kisenyi to Kitebi, I didn’t go with my card and when I went to*
356 *get my drugs from Kitebi, they didn’t give me IPT yet in Kisenyi they had given me for*
357 *three months. I explained to the doctors but they told me they’d give me next time until*
358 *I got fed up and returned to Kisenyi where they have again started me on IPT again”*

359 Female patient.

360 Discussion

361 IPT Completion

362 The goal of the study was to ascertain the IPT completion rate and related variables
363 among those receiving antiretroviral therapy at Kisenyi Health Center IV in Kampala.
364 The cohort of patients under study had an IPT completion rate of 83%, which was
365 considered to be a comparatively high rate. This result is comparable to research from
366 Zimbabwe and India, where studies (26, 27) indicated that 81% of HIV patients have
367 completed IPT. This completion rate is higher than that of the SEARCH HIV test and
368 treat trial, which was done in five communities in Uganda (28), and which Tram et al.
369 reported at 73%.

370 The higher completion level found by our study can be attributed to the efforts of the
371 national Quality Improvement (QI) team at the Ministry of Health founded in January
372 2019 to improve IPT completion as part of a wider continuous quality improvement
373 effort in Uganda.

374 Situational analysis of IPT completion in high-volume facilities and coaching support
375 for these locations across all regions 29 were part of the QI initiatives. The majority of
376 patients receiving INH concurrently with ART lowers the expense of obtaining
377 medication because patients wouldn't need to make as many journeys to the medical
378 institution, which contributes to the relatively high completion rate. Despite the fact that
379 this study indicated that IPT completion rates have increased over time, 17% of
380 patients who begin IPT do not finish the course of treatment. If IPT is not completed,
381 its effectiveness is reduced and the patient is once again at danger of acquiring active
382 TB, which raises morbidity and mortality.

383 **Factors associated with IPT non-completion among patients** 384 **on ART**

385 Males were shown to have a higher prevalence of IPT non-completion than females.
386 This finding is consistent with a study conducted in rural Malawi by Little et al., which
387 found that males were more likely than females to fail to complete the study (29). The
388 typical masculine conduct, lower uptake of facility-based services, cultural precepts,
389 and societal conventions that obstruct men's health-seeking activities and lead to
390 subpar treatment outcomes can all be used to explain this. To increase completion
391 rates, this necessitates focused follow-up with male patients undergoing IPT.

392 The study also found that patients who had a non-suppressed HIV viral load had a
393 higher prevalence of IPT non-completion. HIV viral non-suppression has been
394 reported to be associated with; having active TB, HIV clinical stage, duration of ART,
395 ART regimen, baseline CD4, and ART adherence among other factors (30-32).
396 Additionally, HIV viral non-suppression has been reported to be associated with
397 adherence; defined as a patient's ability to follow a treatment plan, take medications
398 at prescribed times and frequencies and follow restrictions regarding food and other
399 medications (33). Patients who are HIV virally non-suppressed are more likely to have
400 poor ART adherence (30, 34). This, therefore, explains the association between IPT
401 non-completion and viral non-suppression among HIV patients.

402 Patients who did not complete IPT were more likely to be HIV virally non-suppressed.
403 It is possible that non-virally suppressed patients were likely to be non-adherent to
404 ART and other associated medicines including IPT. Targeted follow-up of HIV virally
405 non-suppressing patients on IPT is needed to reduce the prevalence of IPT non-
406 completion in this group.

407 Additionally, the study found that marriage was strongly associated with a lower rate
408 of IPT non-completion than was being single. Married individuals are more likely to be
409 open about their status with their partners (35), which offers emotional and
410 psychological support (36), which has been linked to improved treatment outcomes
411 (37, 38).

412 This can also be explained by the fact that marriage gives patients stability by allowing
413 them to be taken care of while undergoing therapy. IPT completion rates are expected
414 to increase if these patients' wives provide them meals on time and remind them to
415 take their medications.

416 This finding highlights the importance of providing ART patients, as well as those on
417 IPT, with social support networks. These patients can benefit from social and
418 psychological support from services like psychosocial and adherence counseling as
419 part of the HIV care program (39).

420 **Reasons for IPT non-completion**

421 One of the causes of IPT non-compliance, according to this study, is a lack of health
422 education on the topic among HIV patients. In order to improve health literacy,
423 encompassing knowledge and life skills that support individual and communal health,
424 health education entails consciously creating learning opportunities requiring some
425 sort of communication (40). Numerous studies have shown that health education can
426 enhance the effectiveness of patient care (41, 42).

427 The lack of health education among HIV patients on the other hand is related to lower
428 patient adherence and poor treatment outcomes (43, 44). Due to the big volumes of
429 patients that the health workers attend to on clinic days (23, 45), health workers tend
430 to focus on providing drug refills neglecting to provide health education (46). In these

431 circumstances, patients receive drug refills without health education on the benefits of
432 the drugs they have received. These patients are more likely not to adhere to treatment
433 resulting in non-completion.

434 Some of the respondents abandoned IPT due to the pill burden, especially for those
435 that were on medication for other underlying health conditions such as diabetes and
436 hypertension. This finding is similar to studies conducted in Kenya, Swaziland,
437 Zimbabwe, and India which found that pill burden was one of the reasons for IPT non-
438 completion, especially for patients that had to take other drugs for underlying
439 conditions such as hypertension in addition to ART (27, 47-50). This can be explained
440 by the difficulty in concurrent management of all conditions as it can be complicated
441 not only by high pill burden and increased risks of drug-drug interactions but also by
442 overlapping toxicities and immune reconstitution inflammatory syndrome (51).

443 IPT regimens with less frequent dosages compared to INH have been shown to be as
444 effective for TB prevention as INH but with better safety and completion levels. A 3-
445 month weekly course of rifapentine and Isoniazid (3-HP) is as effective for TB
446 prevention as INH, but with better safety and completion levels (52). Other regimens
447 including 4-months of daily Rifampicin (4R), and 3-4 months of daily Isoniazid and
448 Rifampicin (3-4HR) have also been shown to be effective for TB prevention, safe, and
449 for shorter durations compared to 6-9-month course of INH (53-55). Regimens with
450 shorter durations and less frequent dosages should be considered for patients with pill
451 burden challenges to improve IPT completion levels.

452 Distance to the health facility was cited as one of the barriers to IPT completion as
453 patients could not afford transport every month to the health facility to pick up their IPT
454 doses. This echoes findings from studies conducted in Tanzania, Zimbabwe, and

455 Ethiopia which found that patients were discouraged by the need to attend clinic every
456 month combined with the long treatment duration of IPT (26, 56, 57). A significant
457 proportion of patients do not get ART from their nearest facility (58, 59) due to various
458 reasons that include the fear of stigma, and the perception that care at local facilities
459 being of lower quality compared to distant ones (59, 60).

460 This additional distance that the patient has to travel is compounded by unpredicted
461 commodity shortages resulting from challenges in the supply chain management (61)
462 which leads the health workers into giving IPT doses for fewer months compared to
463 ART that was given for a longer period. This results in the need for the patient to attend
464 the ART clinic more frequently to obtain refills which translates into additional costs on
465 the patient's side but also crowding at the clinic.

466 Uganda in 2016 adopted Differentiated Service Delivery (DSD) models for both HIV
467 testing services and treatment to cater to the needs and preferences of the increasing
468 number of clients as well as improve the quality of services and efficiency in service
469 delivery (23). Community-based DSD models have been documented to have benefits
470 both to the patient and the health facility in terms of reducing the cost of obtaining ART
471 on the patient's side, improved patient management, and reduced patient congestion
472 at the health facility (62). These DSD models can further be utilized for giving IPT refills
473 to patients in addition to ART.

474 Another barrier to IPT completion among HIV patients was relocation from one place
475 to another. When patients relocate to new areas within or outside of Kampala, they
476 also transfer to nearby health facilities. The majority of these patients transfer to these
477 sites without proper referral documentation in what is termed "self-transfer" (63). In
478 this case, the transfer-in facility may not offer care continuity (in this case INH) due to

479 a lack of relevant documentation from the transfer-out facility (64). This finding is
480 similar to a study done in Dar es salaam where people living with HIV who were
481 transferred to other clinics within Dar es Salaam region after IPT initiation had
482 significantly lower IPT completion levels compared to those that attended the same
483 clinic (57). These findings are also similar to studies conducted in Zimbabwe and
484 Ethiopia (26, 65). This can also be explained by patients' failure to utilize health
485 facilities in their new localities (63). Linking patient databases to improve access and
486 continuity of care can be explored to improve not only IPT completion but also other
487 treatment like ART.

488 **Study limitations**

489 The study limitations were mainly related to missing and incomplete data since this
490 was a retrospective record review of routinely collected program data. This was
491 overcome by triangulating data from different sources i.e., IPT, ART registers, ART
492 cards, and the UgandaEMR.

493 The study was conducted in one health facility in Kampala city and hence the findings
494 may not be generalizable to other health facilities within other cities and districts in
495 Uganda. Treatment completion was assessed by a patient picking up a refill as a proxy
496 for actual consumption of isoniazid. It is however possible that patients might have
497 returned to pick up another bottle of tablets without consuming all the tablets from the
498 previous refill.

499 The study also explored barriers to IPT completion from the patient's perspective and
500 did not look at the provider and system-related barriers to IPT completion. To
501 effectively improve IPT use, barriers to its completion from the provider's perspective
502 need to be explored as well.

503 Some of the planned interviews by stratification were not conducted as there were no
504 patients/respondents in those strata. The barriers to IPT completion presented
505 represent the patient categories that were interviewed.

506 The barriers to IPT completion explored may have been limited by social desirability
507 bias. This was mitigated by employing unconditional positive regard (66).

508 **Recommendations**

509 1. The health caregivers/health workers need to provide patients with IPT-related
510 health education before IPT initiation. Opportunities to give group health education
511 on clinic days can be leveraged. Patient attitudes towards the therapy and
512 consequently completion levels are likely to improve when patients are fully aware
513 of why they are being initiated on the treatment.

514 2. There's a need for the Ministry of Health and partners to increase availability and
515 access to other regimens of IPT with less frequent dosages compared to a 6-9
516 months daily dose of INH. This will reduce the pill burden, especially on patients
517 with comorbidities, improve adherence and completion levels.

518 3. Health workers and health caregivers should provide and intensify treatment
519 adherence support and counseling to HIV patients who are virally non-suppressed,
520 not only for ART but also IPT.

521 4. There's a need for the Ministry of health to explore the use of biometric systems
522 and linking ART/TB clinics across health facilities to enable patients especially the
523 mobile populations to access ART and IPT at any accredited health facility but also
524 with accurate and timely documentation.

- 525 5. Health facilities should take advantage of community DSD models and exploit them
526 to deliver IPT in addition to ART and other related medications to eligible patients.
527 Additionally, multi-month ART refills synchronized with IPT should also be taken
528 advantage of to improve uptake and completion of IPT.
- 529 6. There's need for further research on factors influencing IPT completion from the
530 health system and provider's perspective.

531

532 **Conclusion**

533 The IPT completion level was found to be relatively high, at 83% among the cohort of
534 patients but still, less than the expected 95%. This corresponds with a general
535 improvement in HIV services and the monitoring of HIV services by health facilities
536 and stakeholders. Being a male, and being HIV virally non-suppressed were
537 significantly associated with a higher prevalence of IPT non-completion. Being
538 married was associated with a lower prevalence of IPT non-completion. Lack of health
539 education, pill burden, distance to the health facility, and relocation were reported as
540 the reasons for failure to complete IPT.

541 **Acknowledgments**

542 Special thanks go to Vicky Kyobutungi for providing a second pair of eyes, and for the
543 input to this work. Thanks also go to Muzoora Enock, Mirembe Annah and Namara
544 Rebecca for the moral support accorded throughout this work.

545 I am also grateful to the Directorate of Public health and Environment at KCCA,
546 administrators, and health workers of Kisenyi Health Centre IV who provided all the

547 records and data that were needed for this research. Special thanks go to all
548 respondents who took part in this study.

549 I also acknowledge the support accorded by my colleagues; Tusabe Joan, Tabwenda
550 Lilian, Nanfuka Harriet, Kisenyi HC IV staff; Thadoues Mugenyi, and Gerald Mwesigye.

551 **Author Contributions**

552 **Conceptualization:** Ian Amany, Anthony Ssebagereka, Richard Mugambe.

553 **Formal analysis:** Ian Amany, Michael Muhoozi.

554 **Funding acquisition:** Ian Amany.

555 **Investigation:** Ian Amany, Anthony Ssebagereka, Richard Mugambe.

556 **Methodology:** Ian Amany, Anthony Ssebagereka, Richard Mugambe.

557 **Project administration:** Ian Amany.

558 **Resources:** Ian Amany.

559 **Software:** Ian Amany, Michael Muhoozi.

560 **Supervision:** Ian Amany, Anthony Ssebagereka, Richard Mugambe.

561 **Visualization:** Ian Amany.

562 **Writing – original draft:** Ian Amany, Dickson Aruhomukama, Anthony Ssebagereka,
563 Richard Mugambe.

564 **Writing – review & editing:** Ian Amany, Dickson Aruhomukama, Anthony
565 Ssebagereka, Richard Mugambe.

566 **References**

- 567 1. WHO. Global tuberculosis report 2018. Geneva, Switzerland: World Health
568 Organization; 2018. WHO/CDS/TB/2018.20. Available from: [http://apps.who.](http://apps.who.int/iris/bitstream...)
569 [int/iris/bitstream ...](http://apps.who.int/iris/bitstream...); 2018.
- 570 2. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of
571 tuberculosis epidemics: the role of risk factors and social determinants. *Social science*
572 *& medicine*. 2009;68(12):2240-6.
- 573 3. Getachew Y, Mekonnen W. Correlates of adherence and utilization of Isoniazid
574 preventive therapy in HIV patients. *Journal of Microbiology and Infectious Diseases*.
575 2015;5(2):45-50.
- 576 4. WHO. Guidelines for intensified tuberculosis case-finding and isoniazid
577 preventive therapy for people living with HIV in resourceconstrained settings. Geneva,
578 Switzerland: WHO; 2011.
- 579 5. Suthar AB, Lawn SD, Del Amo J, Getahun H, Dye C, Sculier D, et al.
580 Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic
581 review and meta-analysis. *PLoS medicine*. 2012;9(7):e1001270.
- 582 6. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et
583 al. The impact of antiretroviral therapy and isoniazid preventive therapy on
584 tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. *AIDS*
585 (London, England). 2007;21(11):1441-8.
- 586 7. Komati S, Shaw PA, Stubbs N, Mathibedi MJ, Malan L, Sangweni P, et al.
587 Tuberculosis risk factors and mortality for HIV infected persons receiving antiretroviral
588 therapy in South Africa. *AIDS (London, England)*. 2010;24(12):1849.
- 589 8. UNAIDS. Country factsheets Uganda: UNAIDS; 2018 [Available from:
590 <https://www.unaids.org/en/regionscountries/countries/uganda>.

- 591 9. MoH U. Uganda population-based HIV impact assessment (UPHIA) 2016–
592 2017. Ministry of Health Kampala; 2019.
- 593 10. MOH. The Uganda National Tuberculosis Prevalence Survey, 2014-2015
594 Survey Report. Kampala Uganda: Ministry of Health; 2018.
- 595 11. WHO. Latent tuberculosis infection: updated and consolidated guidelines for
596 programmatic management. World Health Organization; 2018. Report No.:
597 9241550236.
- 598 12. WHO. Intensified TB case finding and IPT for PLHIV in resource constrained
599 settings 2011 [Available from:
600 [https://apps.who.int/iris/bitstream/handle/10665/44472/9789241500708_eng.pdf?seq](https://apps.who.int/iris/bitstream/handle/10665/44472/9789241500708_eng.pdf?sequence=1)
601 [uence=1](https://apps.who.int/iris/bitstream/handle/10665/44472/9789241500708_eng.pdf?sequence=1).
- 602 13. Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM. The effect of
603 isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients
604 under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC public health.
605 2015;15:346.
- 606 14. Kabali C, von Reyn C, Brooks D, Waddell R, Mtei L, Bakari M, et al. Completion
607 of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in
608 Tanzania. The International Journal of Tuberculosis and Lung Disease.
609 2011;15(11):1515-22.
- 610 15. Abossie A, Yohanes T. assessment of isoniazid preventive therapy in the
611 reduction of tuberculosis among aRT patients in arba Minch hospital, ethiopia.
612 Therapeutics and clinical risk management. 2017;13:361.
- 613 16. MOH. Isoniazid Preventive Therapy in Uganda, a health worker's DGuide.
614 Kampala, uganda: MOH; 2014.

- 615 17. MOH. 100-Day Accelerated Isoniazid Preventive Therapy Scale Up Plan.
616 Kampala, Uganda: Ministry of Health; 2019.
- 617 18. Ayele H, Van Mourik M, Bonten M. Predictors of adherence to isoniazid
618 preventive therapy in people living with HIV in Ethiopia. *The International Journal of*
619 *Tuberculosis and Lung Disease*. 2016;20(10):1342-7.
- 620 19. Tram KH, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A, et al.
621 Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care. *Journal*
622 *of acquired immune deficiency syndromes (1999)*. 2017;76(5):e115-e7.
- 623 20. Thindwa D, MacPherson P, Choko A, Khundi M, Sambakunsi R, Ngwira L, et
624 al. Completion of isoniazid preventive therapy among human immunodeficiency virus
625 positive adults in urban Malawi. *The international journal of tuberculosis and lung*
626 *disease*. 2018;22(3):273-9.
- 627 21. UBOS. National Population and Housing census 2014 Provisional Results.
628 2014.
- 629 22. Yamane T. *Statistics: An Introductory Analysis*, and New York: Harper and Row.
630 1967.
- 631 23. MoH. Consolidated guidelines for prevention and treatment of HIV in Uganda.
632 Ministry of Health Kampala; 2016.
- 633 24. Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: A
634 hybrid approach of inductive and deductive coding and theme development.
635 *International journal of qualitative methods*. 2006;5(1):80-92.
- 636 25. Roberts K, Dowell A, Nie J-B. Attempting rigour and replicability in thematic
637 analysis of qualitative research data; a case study of codebook development. *BMC*
638 *medical research methodology*. 2019;19(1):1-8.

- 639 26. Takarinda K, Choto R, Harries A, Mutasa-Apollo T, Chakanyuka-Musanhu C.
640 Routine implementation of isoniazid preventive therapy in HIV-infected patients in
641 seven pilot sites in Zimbabwe. *Public Health Action*. 2017;7(1):55-60.
- 642 27. Reddy MM, Thekkur P, Ramya N, Kamath PB, Shastri SG, Kumar RB, et al. To
643 start or to complete?—Challenges in implementing tuberculosis preventive therapy
644 among people living with HIV: a mixed-methods study from Karnataka, India. *Global
645 health action*. 2020;13(1):1704540.
- 646 28. Khai Hoan T, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A, et
647 al. Isoniazid preventive therapy completion in the era of differentiated HIV care.
648 *Journal of acquired immune deficiency syndromes (1999)*. 2017;76(5):e115.
- 649 29. Little KM, Khundi M, Barnes GL, Ngwira LG, Nkhoma A, Makombe S, et al.
650 Predictors of isoniazid preventive therapy completion among adults newly diagnosed
651 with HIV in rural Malawi. *The International Journal of Tuberculosis and Lung Disease*.
652 2018;22(4):371-7.
- 653 30. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et
654 al. Factors associated with virological non-suppression among HIV-positive patients
655 on antiretroviral therapy in Uganda, August 2014–July 2015. *BMC infectious diseases*.
656 2017;17(1):1-11.
- 657 31. Chhim K, Mburu G, Tuot S, Sopha R, Khol V, Chhoun P, et al. Factors
658 associated with viral non-suppression among adolescents living with HIV in Cambodia:
659 a cross-sectional study. *AIDS research and therapy*. 2018;15(1):1-10.
- 660 32. Desta AA, Woldearegay TW, Futwi N, Gebrehiwot GT, Gebru GG, Berhe AA,
661 et al. HIV virological non-suppression and factors associated with non-suppression
662 among adolescents and adults on antiretroviral therapy in northern Ethiopia: a
663 retrospective study. *BMC infectious diseases*. 2020;20(1):1-10.

- 664 33. Sahay S, Reddy KS, Dhayarkar S. Optimizing adherence to antiretroviral
665 therapy. *The Indian journal of medical research*. 2011;134(6):835.
- 666 34. Edwards RJ, Lyons N, Samaroo-Francis W, Lavia L-O, John I, Todd S, et al.
667 The expansion of a patient tracer programme to identify and return patients loss to
668 follow up at a large HIV clinic in Trinidad. *AIDS Research and Therapy*. 2021;18(1):1-
669 10.
- 670 35. Amoran O. Predictors of disclosure of sero-status to sexual partners among
671 people living with HIV/AIDS in Ogun State, Nigeria. *Nigerian journal of clinical practice*.
672 2012;15(4):385-90.
- 673 36. Mathews C, Kuhn L, Fransman D, Hussey G, Dikweni L. Disclosure of HIV
674 status and its consequences. *South African medical journal= Suid-Afrikaanse tydskrif*
675 *vir geneeskunde*. 1999;89(12):1238.
- 676 37. Trivedi RB, Ayotte B, Edelman D, Bosworth HB. The association of emotional
677 well-being and marital status with treatment adherence among patients with
678 hypertension. *Journal of behavioral medicine*. 2008;31(6):489.
- 679 38. Aizer AA, Chen M-H, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, et al. Marital
680 status and survival in patients with cancer. *J Clin Oncol*. 2013;31(31):3869-76.
- 681 39. McCord A, Himmelstine CL. Social Protection and HIV global literature review.
682 IOM. 2013.
- 683 40. WHO. Health promotion glossary of terms 2021. 2021.
- 684 41. Levine DM, Green LW, Deeds SG, Chwalow J, Russell RP, Finlay J. Health
685 Education for Hypertensive Patients. *JAMA*. 1979;241(16):1700-3.
- 686 42. Adams RJ. Improving health outcomes with better patient understanding and
687 education. *Risk management and healthcare policy*. 2010;3:61-72.

- 688 43. Cox K, Stevenson F, Britten N, Dundar Y. A systematic review of
689 communication between patients and healthcare professionals about medicine taking
690 and prescribing GKT concordance unit. URL <http://www.concordance.org> (medicines
691 partnership website). 2002.
- 692 44. Tola HH, Shojaeizadeh D, Tol A, Garmaroudi G, Yekaninejad MS, Kebede A,
693 et al. Psychological and Educational Intervention to Improve Tuberculosis Treatment
694 Adherence in Ethiopia Based on Health Belief Model: A Cluster Randomized Control
695 Trial. PLOS ONE. 2016;11(5):e0155147.
- 696 45. Wanyenze RK, Wagner G, Alamo S, Amanyire G, Ouma J, Kwarisima D, et al.
697 Evaluation of the efficiency of patient flow at three HIV clinics in Uganda. AIDS patient
698 care and STDs. 2010;24(7):441-6.
- 699 46. Campbell C, Scott K, Madanhire C, Nyamukapa C, Gregson S. A 'good
700 hospital': nurse and patient perceptions of good clinical care for HIV-positive people
701 on antiretroviral treatment in rural Zimbabwe—a mixed-methods qualitative study.
702 International journal of nursing studies. 2011;48(2):175-83.
- 703 47. Adams L, Mahlalela N, Talbot E, Pasipamire M, Ginindza S, Calnan M, et al.
704 High completion rates of isoniazid preventive therapy among persons living with HIV
705 in Swaziland. The International Journal of Tuberculosis and Lung Disease.
706 2017;21(10):1127-32.
- 707 48. Zirima M, Chifamba N, Mujuru H, Khoza S. Use of isoniazid preventative therapy
708 in HIV infected paediatric patients at Harare Central Hospital. Central African Journal
709 of Medicine. 2018;64(7-9):58-63.
- 710 49. Ahmed F, Malik TZ, Islam F, Muzaffar A. Assessment of Barriers in Initiation
711 and Completion of Isoniazid Preventive Therapy among Household Child Contacts of

- 712 Pulmonary TB Patients in Delhi: A Mixed Method Study. *Community Med.*
713 2020;11(5):227-31.
- 714 50. Ngugi SK, Muiruri P, Odero T, Gachuno O. Factors affecting uptake and
715 completion of isoniazid preventive therapy among HIV-infected children at a national
716 referral hospital, Kenya: a mixed quantitative and qualitative study. *BMC infectious*
717 *diseases.* 2020;20(1):1-11.
- 718 51. Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R. Management of HIV-
719 associated tuberculosis in resource-limited settings: a state-of-the-art review. *BMC*
720 *medicine.* 2013;11(1):1-16.
- 721 52. Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine
722 plus isoniazid for tuberculosis preventive treatment: a systematic review. *Int J Tuberc*
723 *Lung Dis.* 2018;22(12):1422-8.
- 724 53. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al.
725 The effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month
726 regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in
727 children: results of an 11-year randomized study. *Clinical Infectious Diseases.*
728 2007;45(6):715-22.
- 729 54. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four
730 months of rifampin or nine months of isoniazid for latent tuberculosis in adults. *New*
731 *England Journal of Medicine.* 2018;379(5):440-53.
- 732 55. WHO. WHO consolidated guidelines on tuberculosis: tuberculosis preventive
733 treatment: World Health Organization; 2020.
- 734 56. Tadesse Y, Gebre N, Daba S, Gashu Z, Habte D, Hiruy N, et al. Uptake of
735 isoniazid preventive therapy among under-five children: TB contact investigation as
736 an entry point. *PLoS One.* 2016;11(5):e0155525.

- 737 57. Robert M, Todd J, Ngowi BJ, Msuya SE, Ramadhani A, Sambu V, et al.
738 Determinants of isoniazid preventive therapy completion among people living with HIV
739 attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region,
740 Tanzania. *BMC infectious diseases*. 2020;20(1):1-
741 9.
- 742 58. Akullian AN, Mukose A, Levine GA, Babigumira JB. People living with HIV travel
743 farther to access healthcare: a population-based geographic analysis from rural
744 Uganda. *Journal of the International AIDS Society*. 2016;19(1):20171.
- 745 59. Billioux VG, Grabowski MK, Ssekasanvu J, Reynolds SJ, Berman A, Bazaale
746 J, et al. HIV viral suppression and geospatial patterns of HIV antiretroviral therapy
747 treatment facility use in Rakai, Uganda. *AIDS (London, England)*. 2018;32(6):819-24.
- 748 60. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD.
749 Transportation costs impede sustained adherence and access to HAART in a clinic
750 population in southwestern Uganda: a qualitative study. *AIDS and Behavior*.
751 2010;14(4):778-84.
- 752 61. Karimi A, Mishra A, Natarajan KV, Sinha KK. Managing Commodity Stock-outs
753 in Public Health Supply Chains in Developing Countries: An Empirical Analysis.
754 *Production and Operations Management*. 2021;30(9):3116-42.
- 755 62. Kintu TM, Ssewanyana AM, Kyagambiddwa T, Nampijja PM, Apio PK, Kitaka
756 J, et al. Exploring drivers and barriers to the utilization of community client-led ART
757 delivery model in South-Western Uganda: patients' and health workers' experiences.
758 *BMC Health Services Research*. 2021;21(1):1129.
- 759 63. Hickey MD, Omollo D, Salmen CR, Mattah B, Blat C, Ouma GB, et al.
760 Movement between facilities for HIV care among a mobile population in Kenya:
761 transfer, loss to follow-up, and reengagement. *AIDS care*. 2016;28(11):1386-93.

- 762 64. Wilkinson LS, Skordis-Worrall J, Ajose O, Ford N. Self-transfer and mortality
763 amongst adults lost to follow-up in ART programmes in low-and middle-income
764 countries: systematic review and meta-analysis. *Tropical Medicine & International*
765 *Health*. 2015;20(3):365-79.
- 766 65. Ayele HT, van Mourik MS, Bonten MJ. Effect of isoniazid preventive therapy on
767 tuberculosis or death in persons with HIV: a retrospective cohort study. *BMC Infectious*
768 *Diseases*. 2015;15(1):1-8.
- 769 66. Bozarth JD. Unconditional positive regard. *The handbook of person-centred*
770 *psychotherapy and counselling*, 2nd ed. New York, NY: Palgrave Macmillan/Springer
771 *Nature*; 2013. p. 180-92.